Skip to main content
LLY
NYSE Life Sciences

FDA Expands Olumiant Label to Adolescents With Severe Alopecia

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1,183.99
Mkt Cap
$1.114T
52W Low
$712.05
52W High
$1,292.65
52W Position info
66% above low
Off High info
8.4% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

LLY sits 66% above its 52-week low of $712.05.

Summary

The FDA expanded the label for Lilly's Olumiant (baricitinib) to include patients 12 and older with severe alopecia areata, based on Phase 3 data. In the BRAVE-AA-PEDS Phase 3 trial, 42% of adolescents on 4 mg achieved 80% or greater scalp hair coverage at 36 weeks, versus 27% on 2 mg and 5% on placebo. Recommended dosing starts at 2 mg daily, escalating to 4 mg if needed. This broadens the drug's addressable market beyond adults and adds a pediatric indication in a disease with high unmet need. The approval reinforces Lilly's immunology franchise and follows a string of positive regulatory and pipeline developments this year. While Olumiant is not a top revenue driver compared to Mounjaro/Zepbound, the label expansion is a meaningful incremental positive for the company's diversified portfolio.

Updated with a Benzinga report · What changed

Updates

  1. · Benzinga — In the BRAVE-AA-PEDS Phase 3 trial, 42% of adolescents on 4 mg achieved 80% or greater scalp hair coverage at 36 weeks, versus 27% on 2 mg and 5% on placebo. Recommended dosing starts at 2 mg daily, escalating to 4 mg if needed.

At the time of this announcement, LLY was trading at $1,183.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,399.00 info
Change: -$17.22 (-1%) info
Market Cap: $1.315T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,399.00 info
Change: -$56.36 (-4%) info
Market Cap: $1.315T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,399.00 info
Change: -$53.69 (-4%) info
Market Cap: $1.315T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,399.00 info
Change: -$48.85 (-3%) info
Market Cap: $1.315T info
LLY
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,411.12
Real-time Price: $1,399.00 info
Change: -$12.12 (-0.86%) info
Market Cap: $1.315T info